NASDAQ:NTLA - Nasdaq - US45826J1051 - Common Stock - Currency: USD
Investors interested in the Genomics and Synthetic Biology theme may consider adding these three stocks to their portfolio - Intellia Therapeutics (NTLA), uniQure (QURE) and Verve Therapeutics (VERV).
Acadia stock jumps 27% after winning a key patent case for Nuplazid, which will protect the drug's U.S. sales from generic erosion till 2038.
Deep, durable and consistent reductions in TTR were sustained at two years, following a one-time dose of nex-zClinically meaningful improvements in...
The FDA approves INCY's Zynyz both as monotherapy and in combination with chemotherapy for treating advanced anal cancer.
Fast-casual restaurant company Cava reported revenue and earnings that handily beat expectations. Same-restaurant sales growth of 10.8% was especially impressive. The company's forecast calls for same-restaurant sales growth to decelerate as the year goes on.
The mean of analysts' price targets for Intellia Therapeutics (NTLA) points to a 408.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
NTLA reports better-than-expected first-quarter 2025 results. The company provides updates on its pipeline candidates. Shares rise.
NKTR incurs a wider-than-expected loss in the first quarter of 2025. Revenues plunge year over year. Shares fall in after-hours trading.
MIRM reports better-than-expected first-quarter 2025 results. The company raises its 2025 revenue guidance. Shares rise.
AMRN reports better-than-expected results for the first quarter of 2025. However, the top and bottom lines decline on a year-over-year basis.
Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of 12.70% and 14.67%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: BFRI
On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025Dosed first patient in the...
PRGO reports mixed first-quarter 2025 results. The top line declines, largely due to the loss of sales stemming from exited businesses and product lines.
Esperion reports mixed first-quarter 2025 results. Both earnings and revenues decline year over year. Stock falls.
Jazz reports dismal first-quarter results. The company revises its 2025 EPS guidance to account for the recently completed Chimerix acquisition.
Beam Therapeutics incurs a wider-than-expected loss in the first quarter. The company remains focused on pipeline development.
C4 Therapeutics (CCCC) delivered earnings and revenue surprises of 22.92% and 103.03%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: CCCC
CAMBRIDGE, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on...
CorMedix (CRMD) delivered earnings and revenue surprises of 20% and 8.76%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Mentions: CRMD
Orchestra BioMed Holdings, Inc. (OBIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: OBIO
Intellia Therapeutics (NTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Mentions: KRYS
Is it a good or bad thing when a stock surpasses resistance at the 50-day simple moving average?
CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on...
The popular growth investor keeps adding to some of her favorite stocks.
The popular growth investor keeps adding to some of her favorite stocks.
Cantor Fitzgerald thinks the GLP-1 diet drug VK2735 will be a "multi-blockbuster" for Viking stock.
The average of price targets set by Wall Street analysts indicates a potential upside of 392.8% in Intellia Therapeutics (NTLA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
/PRNewswire/ -- Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA)....
The new FDA commissioner had a few key ideas for the agency in an interview with Megyn Kelly.
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Intellia Therapeutics, Inc. ("Intellia" or the "Company") (NASDAQ:...
/PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Intellia Therapeutics ("Intellia" or "the Company") (NASDAQ: NTLA) for...